Key Points
- Insider sale: Abbott VP John Jr. Mccoy sold 585 shares on March 2 at an average $115.58 for $67,614.30, trimming his stake by 2.32% while still holding 24,628 shares (≈$2.85M).
- Q4 and guidance: Abbott reported Q4 EPS of $1.50 (in line) but revenue missed at $11.46B versus ~ $11.8B, set Q1 2026 EPS guidance of 1.120–1.180 and FY 2026 of 5.550–5.800, and declared a $0.63 quarterly dividend (2.2% yield; ex-div Apr 15, pay May 15).
- Market view and catalysts: Wall Street’s consensus is a Moderate Buy (avg. target $137.05) amid mixed analyst revisions, heavy institutional ownership (~75%), and a positive catalyst from FDA approval of the redesigned CardioMEMS Hero, though the stock has recently underperformed.
Abbott Laboratories (NYSE:ABT - Get Free Report) EVP Elizabeth Cushman sold 263 shares of the firm's stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $30,397.54. Following the transaction, the executive vice president owned 38,573 shares in the company, valued at $4,458,267.34. This represents a 0.68% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Abbott Laboratories Stock Performance
Shares of NYSE ABT opened at $113.55 on Wednesday. Abbott Laboratories has a 1 year low of $105.27 and a 1 year high of $141.23. The firm has a market cap of $197.31 billion, a P/E ratio of 30.52, a PEG ratio of 1.82 and a beta of 0.74. The stock has a fifty day moving average price of $116.90 and a two-hundred day moving average price of $125.00. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.18 and a current ratio of 1.58.
Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting the consensus estimate of $1.50. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The business had revenue of $11.46 billion during the quarter, compared to analysts' expectations of $11.80 billion. During the same quarter last year, the business posted $1.34 earnings per share. The company's quarterly revenue was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Research analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.
Abbott Laboratories Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 annualized dividend and a yield of 2.2%. Abbott Laboratories's dividend payout ratio is currently 67.74%.
Wall Street Analyst Weigh In
ABT has been the subject of a number of recent analyst reports. Leerink Partners decreased their price target on Abbott Laboratories from $136.00 to $119.00 and set a "market perform" rating for the company in a research report on Friday, January 30th. Evercore decreased their target price on shares of Abbott Laboratories from $144.00 to $138.00 and set an "outperform" rating for the company in a report on Friday, January 23rd. BTIG Research dropped their target price on shares of Abbott Laboratories from $145.00 to $140.00 and set a "buy" rating on the stock in a research report on Tuesday, February 17th. Sanford C. Bernstein reduced their price target on shares of Abbott Laboratories from $154.00 to $125.00 and set an "outperform" rating for the company in a research report on Friday, January 23rd. Finally, Oppenheimer lowered their price objective on shares of Abbott Laboratories from $140.00 to $132.00 and set an "outperform" rating on the stock in a research report on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Abbott Laboratories currently has a consensus rating of "Moderate Buy" and an average target price of $137.05.
Check Out Our Latest Report on ABT
Key Stories Impacting Abbott Laboratories
Here are the key news stories impacting Abbott Laboratories this week:
- Positive Sentiment: FDA approval of the redesigned CardioMEMS Hero remote heart‑failure monitor — a smaller, lighter reader aimed at improving patient convenience and clinician workflows — strengthens Abbott’s position in heart‑failure management and could increase adoption and revenue over time. How FDA Approval of CardioMEMS Hero Remote Monitor At Abbott (ABT) Has Changed Its Investment Story
- Neutral Sentiment: Multiple insider sales disclosed (several senior/executive officers sold small blocks of shares on Mar. 2). The transactions were modest relative to their remaining holdings, suggesting routine portfolio management rather than a clear signal of company deterioration. John A. Jr. Mccoy Insider Sale
- Negative Sentiment: Near-term earnings pressure: Q4 EPS met estimates but revenue came in below consensus ($11.46B vs. ~$11.80B), which, together with recent softer quarterly trends, has left analysts cautious and weighed on the stock. Abbott (ABT) Stock Sinks As Market Gains: Here's Why
- Negative Sentiment: Shares have underperformed the market over the past six months amid disappointing near‑term results and investor skepticism, which increases sensitivity to any incremental downside news. 2 Reasons to Like ABT and 1 to Stay Skeptical
Institutional Trading of Abbott Laboratories
Hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its holdings in shares of Abbott Laboratories by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker's stock valued at $21,995,501,000 after buying an additional 2,402,408 shares during the last quarter. State Street Corp raised its position in Abbott Laboratories by 2.1% during the fourth quarter. State Street Corp now owns 79,853,782 shares of the healthcare product maker's stock valued at $10,004,880,000 after acquiring an additional 1,627,791 shares in the last quarter. Capital International Investors lifted its stake in Abbott Laboratories by 2.6% in the fourth quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker's stock valued at $7,922,519,000 after acquiring an additional 1,614,706 shares during the last quarter. J. Stern & Co. LLP grew its position in Abbott Laboratories by 12,439.6% in the fourth quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker's stock worth $4,926,279,000 after acquiring an additional 39,005,451 shares in the last quarter. Finally, Capital Research Global Investors increased its stake in shares of Abbott Laboratories by 1.0% during the 4th quarter. Capital Research Global Investors now owns 39,169,239 shares of the healthcare product maker's stock worth $4,907,523,000 after purchasing an additional 400,400 shares during the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.
About Abbott Laboratories
(
Get Free Report)
Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.
In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
